Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 4
2024 6
2025 1
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage.
Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, Rotstein OD, Butler J, Hess DA, Verma S. Park B, et al. Among authors: krishnaraj a. Am J Physiol Heart Circ Physiol. 2024 May 1;326(5):H1159-H1176. doi: 10.1152/ajpheart.00574.2023. Epub 2024 Mar 1. Am J Physiol Heart Circ Physiol. 2024. PMID: 38426865 Free article. Review.
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type 2 diabetes and obesity. ...This review aims to narrow this gap by providing comprehensive and in-depth mechanistic insight into the antiatherosclerotic properties of GLP-1RAs demo …
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type 2 diabetes and obesity. ...This review …
Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
Park B, Dennis F, He AZ, Krishnaraj A, Bakbak E, Dennis CJ, Pan Y, Misner E, Thayanithy V, Lambotharan B, Lambotharan V, Lambotharan A, Mazer CD, Quan A, Teoh H, Hess DA, Verma S. Park B, et al. Among authors: krishnaraj a. Eur Heart J. 2026 Mar 9;47(10):1171-1182. doi: 10.1093/eurheartj/ehaf690. Eur Heart J. 2026. PMID: 40886061 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in individuals living with either diabetes or obesity. Since the turnover of vascular regenerative (VR) stem and progenitor cells has been demonstra …
BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in indiv …
Vascular regenerative cells in cardiometabolic disease.
Bakbak E, Krishnaraj A, Park B, Verma S, Hess DA. Bakbak E, et al. Among authors: krishnaraj a. Curr Opin Cardiol. 2023 Nov 1;38(6):546-551. doi: 10.1097/HCO.0000000000001089. Epub 2023 Aug 30. Curr Opin Cardiol. 2023. PMID: 37668181
Moreover, we provide rationale for the use of VR cells as a biomarker for cardiovascular risk and the use of pharmacological agents to improve VR cell content. RECENT FINDINGS: Recent studies demonstrate the potential of VR cells as a biomarker of cardiovascular ris …
Moreover, we provide rationale for the use of VR cells as a biomarker for cardiovascular risk and the use of pharmacological agents t …
Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study.
Moroney M, Casey JH, Teoh H, Krishnaraj A, Pan Y, Quan A, Patel SK, Dennis F, He AZ, Park B, Verma R, Misner E, Seguchi R, Hassan SMA, Dennis CJ, Meglis G, Pandey A, Butler J, Mazer CD, Byrne RA, Koschinsky ML, Hess DA, Verma S. Moroney M, et al. Among authors: krishnaraj a. Cardiovasc Res. 2025 Nov 22;121(14):2127-2130. doi: 10.1093/cvr/cvaf142. Cardiovasc Res. 2025. PMID: 40883226
AIMS: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD); however, the relationship between Lp(a) and the capacity for vascular repair remains unclear. ...
AIMS: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD); however, the relationship be …
Vascular Regenerative Cell Deficiencies in South Asian Adults.
Krishnaraj A, Bakbak E, Teoh H, Pan Y, Firoz IN, Pandey AK, Terenzi DC, Verma R, Bari B, Bakbak AI, Kunjummar SP, Yanagawa B, Connelly KA, Mazer CD, Rotstein OD, Quan A, Bhatt DL, McGuire DK, Hess DA, Verma S. Krishnaraj A, et al. J Am Coll Cardiol. 2024 Feb 20;83(7):755-769. doi: 10.1016/j.jacc.2023.12.012. J Am Coll Cardiol. 2024. PMID: 38355246 Free article.
METHODS: Between January 2022 and January 2023, 60 South Asian and 60 White European adults with either documented cardiovascular disease or established diabetes with 1 other cardiovascular risk factor were prospectively enrolled. ...
METHODS: Between January 2022 and January 2023, 60 South Asian and 60 White European adults with either documented cardiovascular dis …
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
Bakbak E, Krishnaraj A, Bhatt DL, Quan A, Park B, Bakbak AI, Bari B, Terenzi KA, Pan Y, Fry EJ, Terenzi DC, Puar P, Khan TS, Rotstein OD, Mazer CD, Leiter LA, Teoh H, Hess DA, Verma S. Bakbak E, et al. Among authors: krishnaraj a. Med. 2024 Jul 12;5(7):718-734.e4. doi: 10.1016/j.medj.2024.03.009. Epub 2024 Mar 28. Med. 2024. PMID: 38552629 Free article. Clinical Trial.
BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) showed that icosapent ethyl (IPE) reduced major adverse cardiovascular events by 25%. ...METHODS: Seventy statin-treated individuals with triglycerides 1.50 and <5 …
BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) showed that icosapent ethyl (IPE) …
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.
Krishnaraj A, Bakbak E, Teoh H, Bhatt DL, Quan A, Puar P, Lambotharan B, Kirubaharan A, Firoz IN, Meglis G, Yanagawa B, Bari B, Kirubaharan R, Vijayaraghavan R, Hess DA, Demchuk AM, Mancini GBJ, Tanguay JF, Tardif JC, Voisine P, Leiter LA, Verma S. Krishnaraj A, et al. Med. 2023 Feb 10;4(2):130-138.e1. doi: 10.1016/j.medj.2022.12.008. Epub 2023 Jan 10. Med. 2023. PMID: 36630964 Free article.
BACKGROUND: South Asians (SAs) represent 25% of the world's population and account for >50% of global cardiovascular (CV) deaths, yet they continue to be underrepresented in contemporary clinical trials. ...According to the Health Canada/Canadian Cardiovascular …
BACKGROUND: South Asians (SAs) represent 25% of the world's population and account for >50% of global cardiovascular (CV) deaths, …
Vascular regenerative cell content in South Asians: the key learnings.
Krishnaraj A, Dennis F, Teoh H, Verma S, Hess DA. Krishnaraj A, et al. Curr Opin Cardiol. 2024 Sep 1;39(5):444-450. doi: 10.1097/HCO.0000000000001159. Epub 2024 Jun 7. Curr Opin Cardiol. 2024. PMID: 38847610 Review.
PURPOSE OF REVIEW: We aim to provide a comprehensive examination of the literature linking elevated rates of cardiovascular disease (CVD) in individuals of South Asian ethnicity with the severity of circulating vascular regenerative cell exhaustion. ...
PURPOSE OF REVIEW: We aim to provide a comprehensive examination of the literature linking elevated rates of cardiovascular disease ( …
GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.
Park B, Krishnaraj A, Teoh H, Bakbak E, Dennis F, Quan A, Hess DA, Verma S. Park B, et al. Among authors: krishnaraj a. Am J Physiol Heart Circ Physiol. 2024 Aug 1;327(2):H370-H376. doi: 10.1152/ajpheart.00257.2024. Epub 2024 Jun 14. Am J Physiol Heart Circ Physiol. 2024. PMID: 38874618 Free article. Clinical Trial.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline-recommended therapies for the management of type 2 diabetes (T2D), atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease. We …
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline-recommended therapi …
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.
Bakbak E, Verma S, Krishnaraj A, Quan A, Wang CH, Pan Y, Puar P, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Bakbak E, et al. Among authors: krishnaraj a. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1210-H1222. doi: 10.1152/ajpheart.00141.2023. Epub 2023 Sep 29. Am J Physiol Heart Circ Physiol. 2023. PMID: 37773589 Free article. Clinical Trial.
Sodium glucose-cotransporter 2 (SGLT2) inhibitors have been reported to reduce cardiovascular events and heart failure in people with and without diabetes. These medications have been shown to counter regenerative cell exhaustion in the context of prevalent diabetes. ...Th …
Sodium glucose-cotransporter 2 (SGLT2) inhibitors have been reported to reduce cardiovascular events and heart failure in people with …
15 results